CiMaas moves it’s clinical production site to InSciTe in Sittard-Geleen. Working together in the Biomedical Accelerator Matrix, CiMaas and InSciTe are joining forces to bring a cure for cancer one step closer to reality.
Mr T. Beurskens (Representative Province Limburg on Economy and Knowledge infrastructure) visited CiMaas together with Mrs M. Poulssen (policy advisor Economy and Innovation), Mr M. Cobben (personal assistant) to see current state-of-the-art developments in cell therapy for cancer.
MAASTRICHT, Mercurius Beleggingsmaatschappij B.V. and Werker Beleggingsmaatschappij B.V. invest in CiMaas B.V. to realize cancer immunotherapy. CiMaas is now able to start a clinical trial in late 2017 for lung cancer patients with a cellular vaccine that will stimulate the patients’ own immune system to fight the disease.
The province of Limburg, through LBDF, has awarded CiMaas a subsidy for further development of the new technology for large scale production of NK cell immunotherapy. Under the subsidy, CiMaas collaborates with the department of Haematology of the MUMC+ and an American biotech company to further optimize the treatment.
CiMaas has signed an agreement with London-based Cancer Research Technology, the commercial arm of the charity Cancer Research UK, and the University of Copenhagen under which CiMaas will test a proprietary monoclonal antibody in combination with natural killer cells for the treatment of cancer.